Anti-angiogenic gene therapy of cancer: Current status and future prospects

Luca Persano, Marika Crescenzi, Stefano Indraccolo

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

The discovery of endogenous inhibitors of angiogenesis has made it possible to test the hypothesis that blocking the angiogenic switch may keep tumor growth in check, and has added a new investigational arm to the field of cancer gene therapy. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes proteolysis products of larger molecules with a different function, such as angiostatin, endostatin and vasostatin, modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines/chemokines with marked anti-endothelial activity, such as IL-12, IFN-α, and CXCL10. Pre-clinical studies have clearly indicated that these factors are essentially cytostatic and that they need long-term administration in order to obtain prolonged anti-tumor effects, representing a rational basis for their delivery by a gene therapy approach. The experimental approaches attempted to date, reviewed herein, indicate overall that anti-angiogenic gene therapy has efficacy mainly as an early intervention strategy and that a better understanding of the biological mechanisms underlying resistance to angiogenesis inhibition, as well as appropriate combined treatments, are required to generate a conceptual advancement which could drive the field towards successful management of established tumors.

Original languageEnglish
Pages (from-to)87-114
Number of pages28
JournalMolecular Aspects of Medicine
Volume28
Issue number1
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Gene therapy
Genetic Therapy
Tumors
Angiogenesis Inhibitors
Proto-Oncogene Proteins c-mos
Angiostatins
Endostatins
Proteolysis
Neoplasms
Neoplasm Genes
Interleukin-12
Chemokines
Modulators
Vascular Endothelial Growth Factor A
Switches
Cytokines
Molecules
Growth
Therapeutics

Keywords

  • Angiogenesis
  • Angiostatin
  • Cancer
  • Endostatin
  • Gene therapy
  • Interferon

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Anti-angiogenic gene therapy of cancer : Current status and future prospects. / Persano, Luca; Crescenzi, Marika; Indraccolo, Stefano.

In: Molecular Aspects of Medicine, Vol. 28, No. 1, 02.2007, p. 87-114.

Research output: Contribution to journalArticle

@article{3b7dcf704bed4787a45d879ca5df9d4f,
title = "Anti-angiogenic gene therapy of cancer: Current status and future prospects",
abstract = "The discovery of endogenous inhibitors of angiogenesis has made it possible to test the hypothesis that blocking the angiogenic switch may keep tumor growth in check, and has added a new investigational arm to the field of cancer gene therapy. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes proteolysis products of larger molecules with a different function, such as angiostatin, endostatin and vasostatin, modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines/chemokines with marked anti-endothelial activity, such as IL-12, IFN-α, and CXCL10. Pre-clinical studies have clearly indicated that these factors are essentially cytostatic and that they need long-term administration in order to obtain prolonged anti-tumor effects, representing a rational basis for their delivery by a gene therapy approach. The experimental approaches attempted to date, reviewed herein, indicate overall that anti-angiogenic gene therapy has efficacy mainly as an early intervention strategy and that a better understanding of the biological mechanisms underlying resistance to angiogenesis inhibition, as well as appropriate combined treatments, are required to generate a conceptual advancement which could drive the field towards successful management of established tumors.",
keywords = "Angiogenesis, Angiostatin, Cancer, Endostatin, Gene therapy, Interferon",
author = "Luca Persano and Marika Crescenzi and Stefano Indraccolo",
year = "2007",
month = "2",
doi = "10.1016/j.mam.2006.12.005",
language = "English",
volume = "28",
pages = "87--114",
journal = "Molecular Aspects of Medicine",
issn = "0098-2997",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Anti-angiogenic gene therapy of cancer

T2 - Current status and future prospects

AU - Persano, Luca

AU - Crescenzi, Marika

AU - Indraccolo, Stefano

PY - 2007/2

Y1 - 2007/2

N2 - The discovery of endogenous inhibitors of angiogenesis has made it possible to test the hypothesis that blocking the angiogenic switch may keep tumor growth in check, and has added a new investigational arm to the field of cancer gene therapy. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes proteolysis products of larger molecules with a different function, such as angiostatin, endostatin and vasostatin, modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines/chemokines with marked anti-endothelial activity, such as IL-12, IFN-α, and CXCL10. Pre-clinical studies have clearly indicated that these factors are essentially cytostatic and that they need long-term administration in order to obtain prolonged anti-tumor effects, representing a rational basis for their delivery by a gene therapy approach. The experimental approaches attempted to date, reviewed herein, indicate overall that anti-angiogenic gene therapy has efficacy mainly as an early intervention strategy and that a better understanding of the biological mechanisms underlying resistance to angiogenesis inhibition, as well as appropriate combined treatments, are required to generate a conceptual advancement which could drive the field towards successful management of established tumors.

AB - The discovery of endogenous inhibitors of angiogenesis has made it possible to test the hypothesis that blocking the angiogenic switch may keep tumor growth in check, and has added a new investigational arm to the field of cancer gene therapy. Angiogenesis inhibitors are heterogeneous in origin and potency, and their growing list includes proteolysis products of larger molecules with a different function, such as angiostatin, endostatin and vasostatin, modulators of vascular endothelial growth factor activity, such as sFLT-1, and some cytokines/chemokines with marked anti-endothelial activity, such as IL-12, IFN-α, and CXCL10. Pre-clinical studies have clearly indicated that these factors are essentially cytostatic and that they need long-term administration in order to obtain prolonged anti-tumor effects, representing a rational basis for their delivery by a gene therapy approach. The experimental approaches attempted to date, reviewed herein, indicate overall that anti-angiogenic gene therapy has efficacy mainly as an early intervention strategy and that a better understanding of the biological mechanisms underlying resistance to angiogenesis inhibition, as well as appropriate combined treatments, are required to generate a conceptual advancement which could drive the field towards successful management of established tumors.

KW - Angiogenesis

KW - Angiostatin

KW - Cancer

KW - Endostatin

KW - Gene therapy

KW - Interferon

UR - http://www.scopus.com/inward/record.url?scp=33847247850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847247850&partnerID=8YFLogxK

U2 - 10.1016/j.mam.2006.12.005

DO - 10.1016/j.mam.2006.12.005

M3 - Article

C2 - 17306361

AN - SCOPUS:33847247850

VL - 28

SP - 87

EP - 114

JO - Molecular Aspects of Medicine

JF - Molecular Aspects of Medicine

SN - 0098-2997

IS - 1

ER -